Screening for cervical cancer: recommendations and rationale.

The USPSTF found good evidence from multiple observational studies that screening with cervical cytology (Pap smears) reduces incidence of and mortality from cervical cancer. Direct evidence to determine the optimal starting and stopping age and interval for screening is limited. Indirect evidence suggests most of the benefit can be obtained by beginning screening within 3 years of onset of sexual activity or age 21 (whichever comes first) and screening at least every 3 years (see Clinical Considerations). The USPSTF concludes that the benefits of screening substantially outweigh potential harms.

[1]  H. D. de Vet,et al.  The role of cigarette smoking in the etiology of cervical dysplasia. , 1994, Epidemiology.

[2]  J. Cuzick,et al.  Estimating the efficacy of screening by auditing smear histories of women with and without cervical cancer. The National Co-ordinating Network for Cervical Screening Working Group. , 1996, British Journal of Cancer.

[3]  P. Remington,et al.  The effect of hysterectomy on the risk of an abnormal screening Papanicolaou test result. , 2000, American journal of obstetrics and gynecology.

[4]  Shalini L Kulasingam,et al.  Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral. , 2002, JAMA.

[5]  V. Hasselblad,et al.  Evaluation of cervical cytology. , 1999, Evidence report/technology assessment.

[6]  H. Kitchener,et al.  Efficacy of cervical-smear collection devices: a systematic review and meta-analysis , 1999, The Lancet.

[7]  S Kamen,et al.  The task force. , 1976, Journal of hospital dental practice.

[8]  D T Janerich,et al.  The screening histories of women with invasive cervical cancer, Connecticut. , 1995, American journal of public health.

[9]  T. Nolan,et al.  Cytopathological findings on vaginal Papanicolaou smears after hysterectomy for benign gynecologic disease. , 1996, The New England journal of medicine.

[10]  C. Meijer,et al.  A general primer GP5+/GP6(+)-mediated PCR-enzyme immunoassay method for rapid detection of 14 high-risk and 6 low-risk human papillomavirus genotypes in cervical scrapings , 1997, Journal of clinical microbiology.

[11]  Diane Solomon,et al.  American Cancer Society Guideline for the Early Detection of Cervical Neoplasia and Cancer , 2003, Journal of lower genital tract disease.

[12]  K. Kerlikowske,et al.  The Positive Predictive Value of Cervical Smears in Previously Screened Postmenopausal Women: The Heart and Estrogen/progestin Replacement Study (HERS) , 2000, Annals of Internal Medicine.

[13]  C. Wheeler,et al.  Risk factors for rapid-onset cervical cancer. , 1999, American journal of obstetrics and gynecology.

[14]  J. Cuzick,et al.  HPV testing in primary screening of older women , 1999, British Journal of Cancer.

[15]  W. Winkelstein,et al.  Smoking and cervical cancer--current status: a review. , 1990, American journal of epidemiology.

[16]  G. Giles,et al.  Cancer diagnosis after a report of negative cervical cytology , 1996, The Medical journal of Australia.

[17]  R. D. Dyson Frequency of cervical smear abnormalities within 3 years of normal cytology. , 2000, Obstetrics and gynecology.

[18]  T. Palen,et al.  Cervical cancer screening: American College of Preventive Medicine practice policy statement. , 1996, American journal of preventive medicine.

[19]  K. Dinshaw,et al.  Screening for cervical cancer in India. , 2001, The National medical journal of India.

[20]  Julian Peto,et al.  Prevalence of Human Papillomavirus in Cervical Cancer: a Worldwide Perspective , 1995 .

[21]  Dee W. West,et al.  Smoking and carcinoma in situ of the uterine cervix. , 1983, American journal of public health.